1. Executive Summary & Investment Thesis

Alvotech (NASDAQ: ALVO; CIK: 0001898416), founded in 2013 by pharmaceutical entrepreneur Róbert Wessman and headquartered in Reykjavik, Iceland (with corporate registration in Luxembourg), is an integrated biopharmaceutical enterprise purpose-built to develop, manufacture, and commercialize biosimilar medicines on a global scale. Biosimilars are biologic medical products that are highly similar to, and have no clinically meaningful differences from, an existing FDA- or EMA-approved reference biologic.

Alvotech represents one of the few pure-play, vertically integrated biosimilar platforms worldwide. The company conducts cell-line development, process engineering, clinical trials, and high-titer commercial manufacturing in its state-of-the-art facility in Reykjavik Science Park. Its two lead commercial therapies address multi-billion-dollar immunology markets:

1. Simlandi (AVT02): Biosimilar to AbbVie’s Humira (adalimumab)—the first high-concentration (100 mg/mL), citrate-free interchangeable biosimilar approved by the U.S. FDA.
2. Selarsdi (AVT04): Biosimilar to Johnson & Johnson’s Stelara (ustekinumab)—approved in the U.S., Europe, Canada, and Japan, commercialized in the U.S. by Teva Pharmaceuticals following launch in early 2025.

flowchart TD
    subgraph CorporateFlywheel["Alvotech Operational & Financial Architecture"]
        RND["<b>Reykjavik Biologics Hub</b><br/>High-titer single-use bioreactors<br/>8+ clinical-stage biosimilar pipeline<br/>(Keytruda, Stelara, Humira, Eylea)"]
        PARTNERS["<b>Global Commercial Alliances</b><br/>Teva (U.S.), STADA (Europe)<br/>JAMP (Canada), Fuji Pharma (Japan)<br/>Cost-plus supply + profit split royalties"]
        REV["<b>Commercial Revenue Inflection</b><br/>FY2023: $93.4M -> FY2025: $593.0M<br/>FY2026 Guidance: $650M - $700M<br/>Adj. EBITDA: $180M - $220M"]
        DEBT["<b>$1.3B+ Debt & Interest Burden</b><br/>$965M First-Lien Term Loan (SOFR+6.5%)<br/>$175M Senior Term Loans @ <b>12.50% Cash</b><br/>Annual Cash Interest: <b>>$130M-$145M</b>"]
        DILUTION["<b>Chronic Share Dilution Treadmill</b><br/>Diluted Shares: 110.7M (2021) -> ~315M (2026)<br/>+185% dilution (+23%/yr) to fund cash burn<br/>5-Yr Cumulative Free Cash Flow: <b>-$1.35 Billion</b>"]

        RND --> PARTNERS --> REV
        REV -.->|Consumes Cash Flow| DEBT
        DEBT --> DILUTION
        DILUTION -.->|Subsidizes R&D & Interest| RND
    end

A. Core Thesis Pillars & Two-Minute Monologue (Peter Lynch)

• Stock Archetype: Turnaround
• The Two-Minute Drill: Alvotech has completed the grueling scientific and regulatory journey from a pre-commercial biotechnology cash incinerator to a commercially scaled biologics manufacturer generating nearly $600 Million in annual revenue. With Simlandi and Selarsdi in the market and late-stage biosimilars referencing Keytruda (AVT33), Prolia/Xgeva (AVT03), and Eylea (AVT06) advancing through registrations, Alvotech's pipeline is among the most valuable in the biosimilar sector. However, the capital structure is severely distorted: Alvotech carries **$1.30 Billion in total debt**, faces $175 Million in term loans bearing an onerous 12.50$130 Million in annual cash interest expense—completely wiping out operational cash generation. To service this debt, common shares have expanded by +185% over the past 5 years, creating a chronic dilution treadmill for minority shareholders.
• Runway & Destination: The global biologics patent cliff represents an addressable market exceeding $100 Billion over the coming decade as mega-blockbusters like Keytruda lose exclusivity. However, unless Alvotech can generate self-sustaining free cash flow and refinance its high-cost debt before late 2027, the enterprise value will accrue almost entirely to senior debt holders and GoldenTree Asset Management rather than common equity holders.

B. The Klarman Test: Why Is It Cheap or Trading at $4.54? (Source of Mispricing)

At $4.54 per share ($1.315 Billion market cap), Alvotech is not misunderstood—it is precisely priced for acute refinancing distress and commercial biosimilar margin pressure:

1. Severe Biosimilar Price Erosion: The U.S. Humira biosimilar market has experienced brutal price deflation, with pharmacy benefit managers (PBMs) negotiating net wholesale acquisition cost (WAC) discounts exceeding 80% to 85%, significantly compressing product revenues relative to initial expectations.
2. PBM Formulary Hurdles: Despite securing coveted interchangeable designations, commercial uptake for Simlandi was hindered throughout 2024-2025 by PBM vertical integration, where CVS Caremark, Express Scripts, and OptumRx favored private-label arrangements (e.g., Cordavis) or co-preferred status with AbbVie.
3. Punitive Debt Service: Investors are acutely aware that Alvotech’s $175 Million Senior Term Loan Facility carries an aggressive 12.50% cash coupon (payable monthly), signaling that conventional institutional credit markets view the enterprise as distressed credit.

C. Catalysts & Value-Realization Path

• Internal Catalysts: Launch and ramp of Selarsdi (AVT04) in the U.S. via partner Teva; FDA approvals for AVT03 (denosumab) and AVT06 (aflibercept); execution of operational efficiencies at the Reykjavik plant to lower unit batch costs.
• External Catalysts: Federal Trade Commission (FTC) antitrust scrutiny into PBM formulary rebate walls; health insurer mandates transitioning patients to lower-cost biosimilars; comprehensive debt refinancing extending maturities to 2030+ at single-digit interest rates.

---

2. Economic Moat, SES & Competitive Durability

• Moat Rating: Narrow
• Moat Trend: Stable

Alvotech possesses a Narrow Economic Moat derived from high regulatory switching costs, specialized biologic manufacturing engineering, and first-to-market interchangeable designations. However, the moat is strictly constrained by the commoditizing nature of biosimilar price competition and the absence of direct brand pricing power.

flowchart LR
    subgraph MoatSources["Alvotech Moat Architecture"]
        M1["<b>Interchangeable FDA Status</b><br/>Allows pharmacist substitution<br/>without prescriber intervention<br/>(Simlandi AVT02)"]
        M2["<b>High-Titer Reykjavik Bioreactors</b><br/>Purpose-built automated facility<br/>Custom perfusion & fed-batch tech<br/>Scale economies in bulk drug substance"]
        M3["<b>Global Distribution Network</b><br/>Teva, STADA, JAMP, Fuji Pharma<br/>Commercial infrastructure outsourced<br/>Shared regulatory filing burden"]
    end

    subgraph MoatConstraints["Moat Degradation Forces"]
        C1["<b>Brutal Price Deflation</b><br/>Multi-competitor entry driving<br/>80%+ discounts off reference price"]
        C2["<b>PBM Monopsony Power</b><br/>Rebate walls protect originator drugs<br/>Private-label captive supplier deals"]
        C3["<b>No Proprietary Molecule IP</b><br/>Reference biologics have expired IP<br/>Competing biosimilars enter simultaneously"]
    end

    MoatSources -->|Offset By| MoatConstraints

A. High Customer Switching Costs & Biologic Complexity

Unlike small-molecule generic drugs that are chemically synthesized, biosimilars are large, complex proteins (molecular weight ~150,000 Daltons) manufactured in living host cells. Developing a biosimilar requires reverse-engineering the originator’s post-translational modifications (glycosylation, phosphorylation) through extensive analytical characterization, pharmacokinetic (PK) studies, and comparative clinical trials—a multi-year process typically costing $100 Million to$200 Million per asset.

Furthermore, achieving an interchangeability designation from the U.S. FDA requires specialized clinical switching studies (multiple switches between reference biologic and biosimilar), allowing U.S. pharmacists to substitute the biosimilar without consulting the prescribing physician. Alvotech’s Simlandi was the first high-concentration (100 mg/mL), citrate-free interchangeable adalimumab approved, providing a defensive moat against non-interchangeable low-concentration formulations.

B. The Biosimilar Commercial Model & Global Partnership Network

Alvotech does not fund direct commercial field sales forces. Instead, the company operates an asset-light commercial alliance model:

• Teva Pharmaceuticals: Strategic commercialization partner in the United States, responsible for market access, PBM formulary placement, and commercial distribution for Simlandi, Selarsdi, and future pipeline assets.
• STADA Arzneimittel: European commercialization partner with an extensive hospital and specialty pharma distribution footprint.
• Regional Partners: JAMP Pharma (Canada), Fuji Pharma (Japan), Cipla (Australia/New Zealand), and Advanz Pharma (Europe).

Under these agreements, Alvotech handles development, clinical trials, and manufacturing, while commercial partners bear all marketing and selling expenses. Alvotech receives upfront licensing milestones, regulatory milestone payments, supply price transfers (cost-plus or fixed unit transfer price), and profit-sharing royalties ranging from 30% to 50% of net market sales.

C. Regulatory Hurdles & Manufacturing Compliance Track Record

Developing biosimilars entails severe regulatory execution risk. Between 2022 and 2024, Alvotech’s Reykjavik manufacturing facility was subjected to multiple FDA inspections that resulted in Form 483 inspection observations and successive Complete Response Letters (CRLs) regarding facility environmental controls, stopping mechanisms, and process validation. These delays postponed the U.S. commercial launch of AVT02 by nearly two years, allowing competitors like Sandoz (Hyrimoz), Organon (Hadlima), and Boehringer Ingelheim (Cyltezo) to enter the U.S. market first. While Alvotech resolved these observations and secured FDA approvals in early 2024, the episode demonstrates the fragility of single-site biologics manufacturing.

D. Terry Smith Gross Margin Shield & Pricing Power Analysis

Under Terry Smith’s investment criteria, an elite business must maintain a Gross Profit Margin >= 60% to shield profits from inflation and commodity shocks:

• Alvotech generated an adjusted gross profit margin of 54.0% in H1 2026 (and 55.0% in H1 2025), falling short of the Terry Smith 60% threshold.
• In biosimilars, gross margins face relentless structural erosion over product lifecycles. As 5 to 10 biosimilar competitors enter each therapeutic category (e.g., adalimumab, ustekinumab), price competition drives prices down by 70% to 90%, eroding unit economics and requiring continuous volume growth simply to maintain flat gross profit dollars.

E. Mohnish Pabrai Spawner DNA: The 8+ Candidate Pipeline

Mohnish Pabrai evaluates whether a company possesses the internal capability to spawn new profitable lines of business. Alvotech’s pipeline is robust and targets the largest biologic franchises in medicine:

• AVT02 (Simlandi / adalimumab): Referencing Humira ($20B+ peak global market).
• AVT04 (Selarsdi / ustekinumab): Referencing Stelara ($10B+ peak global market).
• AVT03 (denosumab): Referencing Prolia/Xgeva ($6B global market); Phase 3 completed.
• AVT05 (golimumab): Referencing Simponi/Simponi Aria ($2B global market); Phase 3 ongoing.
• AVT06 (aflibercept): Referencing Eylea ($9B global market); Phase 3 completed.
• AVT16 (etanercept): Referencing Enbrel ($4B global market).
• AVT23 (omalizumab): Referencing Xolair ($3.5B global market).
• AVT33 (pembrolizumab): Referencing Keytruda ($25B+ mega-blockbuster); Phase 1/3 clinical program in development.

However, unlike true Pabrai “Spawners” (such as Alphabet or Berkshire Hathaway) that fund adjacent incubations entirely from organic free cash flow, Alvotech has funded this pipeline through $1.3B+ of debt and$500M+ of dilutive equity issuances.

---

3. Financial Quality & Balance Sheet Fortress

• Solvency Classification: Vulnerable
• Net Debt / EBITDA: 8.2x (Based on FY2025 Adjusted EBITDA of $137M)
• Interest Coverage: < 1.0x (EBIT of $78.2M vs Cash Interest >$130M)

A. The 4 Knockout Quality Gates Audit (Rule 07, Section 2)

+==================================================================================================+
|                        THE 4 KNOCKOUT DISQUALIFICATION GATES (ALVO)                              |
+==================================================================================================+

[X] GATE K1: THE CIRCLE OF COMPETENCE & SIMPLICITY GATE (Buffett, Munger, Pabrai, Li Lu)
    --> FAIL: Biosimilar development involves opaque multi-party profit splits with PBMs, complex
        patent litigation (BPCIA), and single-facility biological manufacturing risks that defy simple
        two-minute economic predictability. Disqualified from conservative quality consideration.

[ ] GATE K2: THE SECTOR & FRAGILITY EXCLUSION SCREEN (Terry Smith)
    --> PASS: Operating biopharmaceutical enterprise; non-bank, non-insurance, non-airline.

[X] GATE K3: THE FINANCIAL DISTRESS & REFINANCING WALL (Graham, Marks, Ackman)
    --> CRITICAL FAIL: Net Debt / EBITDA is 8.2x (far exceeding the 3.5x maximum ceiling).
        Interest Coverage is < 1.0x (Cash interest expense of >$130M devours operating profit).
        Upcoming maturity wall: $175M Senior Term Loans at 12.50% interest mature on Dec 31, 2027,
        unfunded by negative TTM Owner Free Cash Flow (-$122M). Automatic DISQUALIFICATION ("AVOID").

[X] GATE K4: FORENSIC ACCOUNTING & EARNINGS INTEGRITY GATE (Terry Smith, Graham, Munger)
    --> CRITICAL FAIL: Cumulative 5-year Free Cash Flow is -$1.35 Billion while reporting positive
        GAAP net income of $27.9M in 2025 (Terry Smith conversion is -410.7%). Common shares diluted
        by +185% over past 5 years (110.7M to ~315M, >23%/yr), grossly breaching the <=3.0%/yr threshold.
        Automatic DISQUALIFICATION ("AVOID").

Historical SEC XBRL Financial Statements & Metrics Matrix:

The following table compiles audited financial results from Alvotech’s SEC Form 20-F annual reports and Form 6-K interim disclosures (converted to USD millions, except per-share metrics):

Metric	FY2021	FY2022	FY2023	FY2024	FY2025	H1 2026	TTM (mid-2026)
Total Revenue	$39.5	$85.3	$93.4	$490.8	$593.0	$211.9	$498.8
Product & Supply Revenue	$0.0	$2.5	$3.8	$175.2	$310.5	$105.9	$211.7
License & Milestone Revenue	$39.5	$82.8	$89.6	$315.6	$282.5	$105.7	$287.1
Cost of Sales	$(3.2)	$(25.4)	$(48.1)	$(241.6)	$(272.8)	$(97.5)	$(228.7)
Gross Profit	$36.3	$59.9	$45.3	$249.2	$320.2	$114.4	$270.1
Gross Margin %	91.9%	70.2%	48.5%	50.8%	54.0%	54.0%	54.1%
Research & Development (R&D)	$(185.2)	$(214.5)	$(235.4)	$(225.8)	$(248.5)	$(98.2)	$(221.9)
Selling, General & Admin (SG&A)	$(86.6)	$(191.8)	$(164.8)	$(125.4)	$(131.2)	$(58.4)	$(124.0)
Operating Income (EBIT)	$(235.5)	$(346.4)	$(354.9)	$69.6	$78.2	$(42.2)	$(75.8)
Net Finance Costs / Interest Expense	$(52.1)	$(108.4)	$(162.5)	$(142.1)	$(138.4)	$(72.5)	$(148.8)
Fair Value Gain/(Loss) on Derivatives	$186.1	$(58.8)	$(34.3)	$(159.4)	$88.1	$48.9	$119.4
GAAP Net Income / (Loss)	$(101.5)	$(513.6)	$(551.7)	$(231.9)	$27.9	$(65.8)	$(105.2)
Diluted Common Shares (Period-End, M)	110.7	197.7	227.3	267.9	289.7	289.7	~315.0*
GAAP EPS ($)	$(0.92)	$(2.60)	$(2.43)	$(0.87)	$0.10	$(0.23)	$(0.33)
Operating Cash Flow (OCF)	$(228.2)	$(312.4)	$(312.2)	$(236.8)	$(50.2)	$(45.8)	$(62.5)
Capital Expenditures (CapEx)	$(20.5)	$(37.9)	$(33.2)	$(53.7)	$(64.5)	$(28.4)	$(59.2)
Stock-Based Compensation (SBC)	$0.0	$10.3	$18.0	$7.6	$7.4	$3.5	$7.3
Owner Free Cash Flow (OCF-CapEx-SBC)	$(248.7)	$(360.6)	$(363.4)	$(298.1)	$(122.1)	$(77.7)	$(129.0)
Cash & Cash Equivalents	$17.6	$66.4	$11.2	$51.4	$172.4	$142.8	$142.8
Total Debt (Carrying Value)	$403.7	$784.5	$998.2	$1,068.6	$1,299.1	$1,292.0	$1,367.0*
Net Debt (Total Debt - Cash)	$386.1	$718.1	$987.0	$1,017.2	$1,126.7	$1,149.2	$1,224.2*
Total Shareholders’ Equity (Deficit)	$(135.6)	$(564.4)	$(932.5)	$(412.8)	$(284.5)	$(245.2)	$(160.0)
Adjusted EBITDA	$(195.0)	$(280.0)	$(275.0)	$110.0	$137.0	$46.9	$130.2
Net Debt / Adj. EBITDA	N/A	N/A	N/A	9.2x	8.2x	N/A	9.4x

*Reflects July 2026 equity offering of $164.6M net (~25.3M new shares) and new$75M senior term loan facility drawn with GoldenTree Asset Management.

B. Post-Acquisition Capital Structure & Maturity Schedule

Alvotech’s debt structure represents one of the heaviest leverage loads in the specialty biopharmaceutical sector:

• Senior Secured First Lien Term Loan Facility (Amended June 2025): ~$965 Million principal maturing in **July 2029**, bearing variable interest of SOFR + 6.50$110 Million in annual cash interest.
• Senior Term Loan Facility (December 2025 & July 2026): $175 Million total ($100M entered in December 2025, expanded by $75M in July 2026) managed by GoldenTree Asset Management. Maturing on **December 31, 2027**, this loan bears a punitive interest rate of **12.50$21.9 Million in annual interest).
• Convertible Senior Bonds due 2030 (December 2025): $108 Million in senior unsecured convertible bonds due **December 2030**, carrying a 6.875$7.4 Million annual interest) convertible at $5.9224 per share.
• Combined Annual Cash Interest Burden: Exceeds $139 Million per year, draining virtually all operating cash flows and preventing internal capital accumulation.

---

4. Capital Allocation & Management Track Record

• Return on Invested Capital (ROIC): 7.3% (FY2025 GAAP operating income vs negative equity + debt; fundamentally negative on true cash basis)
• **Buffett $1 Retained Earnings Test**: **Severely Failing** (Cumulative net losses exceed$1.4 Billion since 2021)
• Share Dilution Track Record (2021 to Mid-2026): +184.6% (110.7M to ~315M shares)
• Capital Allocation Stewardship: Distressed / Value Destructive for Equity Holders

flowchart TD
    subgraph DebtDilutionEngine["Alvotech Capital Allocation Flywheel"]
        DEBTRUN["<b>Aggressive Debt Incurrence</b><br/>$1.3B+ Borrowed from GoldenTree & Lenders<br/>$175M Senior Term Loans @ 12.50% Cash Interest<br/>Total Cash Interest: >$139M/year"]
        CASHBURN["<b>Manufacturing & Clinical R&D</b><br/>Reykjavik High-Titer Plant ($60M CapEx/yr)<br/>8+ Biosimilar Clinical Programs ($220M R&D/yr)<br/>Owner Free Cash Flow: <b>-$122M to -$129M TTM</b>"]
        DILUTION["<b>Emergency Equity Offerings</b><br/>Shares Exploded from 110.7M to ~315M (+185%)<br/>$165M Raised in Mid-2026 to Avert Cash Crunch<br/>Book Value per Share Permanently Diluted"]
        CLIFF["<b>December 31, 2027 Refinancing Wall</b><br/>$175M Senior Term Loan Due<br/>Credit Covenants & High Yield Environment"]

        DEBTRUN --> CASHBURN
        CASHBURN --> DILUTION
        DILUTION --> CLIFF
        CLIFF -.->|Requires Rollover or Dilution| DEBTRUN
    end

A. Return on Capital (ROIC / ROCE) & Economic Profit

Under Terry Smith and Charlie Munger’s principles, an outstanding business must generate consistent ROIC >= 20% comfortably exceeding its Weighted Average Cost of Capital (WACC).

• Alvotech’s weighted cost of debt alone exceeds 11.5%, while its cost of equity exceeds 15.0% (blended WACC ~12.5%).
• With negative operating cash flows and GAAP EBIT of $78.2M against Invested Capital exceeding$1.0B, Alvotech’s economic profit (ROIC - WACC) is deeply negative, destroying economic capital on a per-share basis.

B. The Buffett $1 Retained Earnings Test

Warren Buffett’s $1 test dictates that for every dollar of retained earnings withheld from shareholders, the enterprise must create at least one dollar of incremental market value:

• Since 2021, Alvotech has retained zero positive cumulative earnings, accumulating over $1.4 Billion in comprehensive net losses.
• Over the same span, external capital providers injected over $1.5 Billion in debt and equity, yet Alvotech's current equity market capitalization stands at just **$1.315 Billion**. The enterprise has destroyed substantial economic capital relative to total cumulative funding.

C. Chronic Share Dilution Surveillance

Peter Lynch and Benjamin Graham insist that value investors guard against aggressive share issuance:

• In 2021, Alvotech had 110.7 Million diluted common shares outstanding.
• By FY2023, shares reached 227.3 Million.
• By FY2025, shares expanded to 289.7 Million.
• Following the July 2026 equity capital raise of $164.6M net, share count reached ~315.0 Million.
• This represents a +184.6% expansion in share count in under 5 years (an annualized dilution rate exceeding 23.2% per year). Any operational gains achieved by commercializing Simlandi or Selarsdi are heavily diluted before reaching the common shareholder.

D. Leadership, Governance & Incentive Alignment

Alvotech is led by founder and Chairman Róbert Wessman, an experienced generic pharmaceutical executive who previously built and led Actavis. Wessman’s investment vehicle, Aztiq Pharma, alongside key strategic backers, holds substantial insider equity ownership. Management has demonstrated exceptional tenacity in constructing the Reykjavik facility and securing landmark interchangeable FDA approvals. However, capital allocation has prioritized aggressive pipeline expansion funded by high-yield mezzanine-style debt facilities with GoldenTree, creating existential financial risk for ordinary shareholders.

---

5. Valuation, Reverse DCF & Margin of Safety

• Current Market Price: $4.54
• Intrinsic Fair Value (Probability-Weighted Triangulation): $4.08
• Margin of Safety (MOS): -11.3% (Overvalued by 11.3%)
• Seth Klarman Downside Bear Floor: $1.50 (Debt Overhang Restructuring Floor)
• Net Debt per Share: **$3.89** ($1.224B / 315M shares)
• Current Enterprise Value (EV): **$2.54 Billion** ($1.315B market cap + $1.224B net debt)

flowchart TD
    subgraph TriangulatedDCF["ValueMark Triangulated 3-Scenario Engine ($4.08 Fair Value)"]
        direction TB
        BEAR["<b>Bear Case (25% Weight) -> $1.50</b><br/>Humira/Stelara Biosimilar Price Collapse (-85%)<br/>2027 Refinancing Crisis forces massive equity dilution<br/><i>Klarman Distress Floor: $1.50 per share</i>"]
        BASE["<b>Base Case (50% Weight) -> $3.80</b><br/>2026 Guidance Met ($675M Rev, $200M EBITDA)<br/>Selarsdi Scales | Denosumab/Eylea Approved in 2027<br/>Owner FCF turns positive to $60M ($0.19/sh)<br/><i>Baseline Intrinsic Fair Value: $3.80 per share</i>"]
        BULL["<b>Bull Case (25% Weight) -> $7.20</b><br/>Global Biosimilar Supercycle | Keytruda Advance<br/>Debt Refinanced at SOFR+3.5% (saves $50M/yr)<br/>Owner FCF surges to $150M+ ($0.48/sh)<br/><i>Optimistic Platform Value: $7.20 per share</i>"]
    end

    TRI["<b>Probability-Weighted Intrinsic Fair Value: $4.08</b><br/>(0.25 x $1.50) + (0.50 x $3.80) + (0.25 x $7.20) = $4.08<br/>Current Price: $4.54 | Margin of Safety: <b>-11.3%</b><br/><b>Dynamic Action Verdict: AVOID</b> (Failed 2 Knockout Gates)"]

    BEAR --> TRI
    BASE --> TRI
    BULL --> TRI

A. Triangulated 3-Scenario DCF Valuation Engine (Rule 05)

Under ValueMark Rule 05, specialty biotechnology companies undergoing commercial turnaround are evaluated across three discrete, probability-weighted DCF scenarios incorporating a 12.0% cost of capital to reflect high financial leverage and commercial pricing risks:

1. Bear Case (25% Weight - Seth Klarman Downside Floor): $1.50 per share
   • Assumptions: Biosimilar price erosion accelerates; U.S. PBMs demand 85%+ discounts on Selarsdi (AVT04) while Simlandi volumes stagnate. Annual cash interest (> $139M) outstrips operational cash generation, draining liquid reserves. Arriving at the December 31, 2027 maturity of the$175M GoldenTree term loan without positive FCF, Alvotech is forced into a punitive, highly dilutive equity recapitalization (issuing 150M+ shares below $2.00) or a debt-for-equity restructuring. Discounted residual equity value compresses to **$1.50 per share**.
2. Base Case (50% Weight - Baseline Commercial Execution & Deleveraging): $3.80 per share
   • Assumptions: Alvotech achieves the midpoint of full-year 2026 guidance ($675M revenue,$200M Adjusted EBITDA). Teva successfully expands Selarsdi’s U.S. commercial adoption to 10% volume share of ustekinumab. AVT03 (denosumab) and AVT06 (aflibercept) secure approvals in 2027, lifting net revenues to $900M+ by 2028. After CapEx ($60M) and cash interest ($130M), Owner Free Cash Flow turns positive to$50M-$70M (~$0.18-$0.22/share) by 2028. Applying a 14.0x terminal FCF multiple discounted at 12.0$3.80 per share**.
3. Bull Case (25% Weight - Biosimilar Supercycle & Debt Refinancing): $7.20 per share
   • Assumptions: Rapid global biosimilar adoption drives revenues past $1.25 Billion by 2029. Commercial manufacturing scale at Reykjavik improves gross margins to 60$350M+, Alvotech successfully refinances its high-yield debt facilities with conventional investment-grade/high-yield bonds at 6.5%, saving over $50 Million annually in cash interest. Owner Free Cash Flow surges to$150M+ ($0.48/share). Valued at 16.0x FCF discounted at 11.0$7.20 per share**.

$\text{Probability-Weighted Intrinsic Fair Value} = (0.25 \times \$1.50) + (0.50 \times \$3.80) + (0.25 \times \$7.20) = \$0.375 + \$1.900 + \$1.800 = \mathbf{\$4.08}$

B. The Seth Klarman Bear-Floor Invariant

Under Rule 07 Section 5, value investors must enforce the Seth Klarman Bear-Floor Rule: $\text{Strong Buy Floor Condition: Current Price} \le \text{Bear-Case Fair Value} \times 1.05$ With our conservative Bear-Case Restructuring Floor calculated at $1.50**, the maximum permissible purchase price for high-conviction value investment is **$1.58. At the current market quote of $4.54, ALVO trades +202.7% above its Seth Klarman Bear Floor.

Furthermore, ALVO exhibits a negative Margin of Safety of -11.3% against our probability-weighted fair value ($4.08). Coupled with failures at Knockout Gates K3 and K4, Rule 07 Section 5 strictly mandates:

“Score < 60 (Failing Quality Gate): NEVER ELIGIBLE for Strong Buy or Buy. Action Verdict: AVOID (Value Trap / Fragile).”

C. Reverse DCF Analysis (“Expectations Investing”)

Running an inverse DCF at the current market price of **$4.54** ($1.315B market cap, $2.54B Enterprise Value) reveals what Mr. Market is pricing in:

• To justify $4.54 under a 12.0$115 Million annually** by 2028 (requiring EBITDA to exceed $300 Million and interest expense to fall substantially).
• This implies a flawless commercial ramp across Selarsdi, AVT03, and AVT06, zero regulatory delays, and seamless debt refinancing without shareholder dilution. Given Alvotech’s historical cash burn (-$129M TTM Owner FCF) and 8.2x leverage, current market prices provide zero margin of safety against execution friction.

---

6. The 100-Point Master Value Score Breakdown

### Master Value Scorecard (Rule 07)
- **Pillar 1: Business Model Quality & Simplicity**: 10 / 20 pts
  - Simplicity (1/5) | Repeat Demand (4/5) | Lynch Archetype (2/5) | Secular Runway (3/5)
- **Pillar 2: Economic Moat Durability & Spawner DNA**: 12 / 25 pts
  - Moat Depth (4/8) | Moat Trend (3/6) | Gross Margin Shield (3/4) | SES Flywheel (1/4) | Spawner DNA (1/3)
- **Pillar 3: Financial Fortress & Solvency**: 2 / 20 pts
  - Leverage (0/6) | Working Capital (1/4) | Maturity Ladder (0/3) | Cash Conversion (0/4) | Red Flag Screen (1/3)
- **Pillar 4: Capital Allocation & Management Integrity**: 3 / 15 pts
  - ROIC/ROCE (0/5) | Incremental Returns / $1 Test (1/4) | Buyback Discipline (0/3) | Insider Alignment (2/3)
- **Pillar 5: Valuation, Margin of Safety & Asymmetry**: 1 / 20 pts
  - Margin of Safety (0/8) | Klarman Bear Floor (0/4) | Earnings/FCF Yield (0/3) | Lynch PEG (0/3) | Dhandho Asymmetry (1/2)

- **TOTAL MASTER VALUE SCORE**: **28 / 100** -> **Failing Quality Gate / Avoid**
- **Action Verdict**: **Avoid** (MOS: -11.3%)

---

7. What Would Invalidate the Thesis?

1. Comprehensive Long-Term Debt Refinancing: Successfully refinancing the $175 Million 12.50$965 Million first-lien term loan into long-term fixed-rate debt maturing past 2031 at an effective interest rate <= 7.0%, eliminating the 2027 maturity wall and reducing annual cash interest expense by >= $50 Million.
2. Inflection to Sustainable Positive Owner Free Cash Flow: Demonstrating two consecutive fiscal quarters of positive Owner Free Cash Flow (OCF - CapEx - SBC) exceeding $30 Million per quarter, proving that commercial manufacturing of Simlandi and Selarsdi can generate self-funding cash economics.
3. Breakthrough PBM Formulary Dominance for Selarsdi: Commercial partner Teva securing exclusive or co-preferred formulary status for Selarsdi (AVT04) with major PBMs (Express Scripts, CVS Caremark, OptumRx), capturing >= 20% of the U.S. ustekinumab volume market within 12 months without triggering destructive price war erosion.
4. Equity Capitulation to Seth Klarman Bear Floor: Extreme equity market liquidation driving ALVO shares down to or below $1.50 per share, which would align the market quotation with our Bear-Case Restructuring Floor and unlock a >60% Margin of Safety against base-case fair value.